PPD will work with J&J’s Belgian subsidiary, Janssen Pharmaceutica, on drugs for bowel, skin and lung diseases in a $330m in a deal announced yesterday.
Microbia and Forest Laboratories have penned a multi-million dollar
deal over the former's first-in-class drug to treat irritable bowel
syndrome (IBS).
Microbia has presented clinical data that shows its first-in-class
drug for the treatment of constipation-predominant irritable bowel
syndrome (IBS-C) and chronic constipation (CC), demonstrated
promising pharmacodynamic effects.